BioNTech (BNTX) Set to Announce Quarterly Earnings on Monday

BioNTech (NASDAQ:BNTX) is set to release its earnings data before the market opens on Monday, May 6th. Analysts expect BioNTech to post earnings of ($0.45) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

BioNTech (NASDAQ:BNTX) last announced its earnings results on Wednesday, March 20th. The company reported $2.05 EPS for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. On average, analysts expect BioNTech to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioNTech Stock Up 0.5 %

Shares of NASDAQ:BNTX opened at $92.72 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.43 and a quick ratio of 9.26. The stock has a market cap of $22.04 billion, a P/E ratio of 22.39 and a beta of 0.25. BioNTech has a 1-year low of $85.21 and a 1-year high of $125.83. The firm has a fifty day moving average price of $90.56 and a 200 day moving average price of $96.01.

Analyst Ratings Changes

A number of research analysts have recently issued reports on BNTX shares. BMO Capital Markets dropped their target price on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a report on Thursday, March 21st. UBS Group reduced their price target on BioNTech from $110.00 to $101.00 and set a “neutral” rating for the company in a report on Wednesday, March 27th. The Goldman Sachs Group cut their price objective on BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. Canaccord Genuity Group reissued a “buy” rating and set a $171.00 price objective on shares of BioNTech in a report on Thursday, March 21st. Finally, JPMorgan Chase & Co. dropped their target price on shares of BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has an average rating of “Hold” and an average target price of $120.40.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.